Department of Medical Oncology, Translational Research Institute, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Translational Research Institute & Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
J Exp Clin Cancer Res. 2021 Feb 18;40(1):74. doi: 10.1186/s13046-021-01872-3.
Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies. Response rates are however suboptimal, and despite considerable efforts, predicting response to immune checkpoint inhibitors ahead of their administration in a given patient remains elusive. The study of the dynamics of the immune system and of the tumor under immune checkpoint blockade brought insight into the mechanisms of action of these therapeutic agents. Equally relevant are the mechanisms of adaptive resistance to immune checkpoint inhibitors that have been uncovered through this approach. In this review, we discuss the dynamics of the immune system and of the tumor under immune checkpoint blockade emanating from recent studies on animal models and humans. We will focus on mechanisms of action and of resistance conveying information predictive of therapeutic response.
免疫检查点抑制剂在多种实体瘤以及血液恶性肿瘤亚组中提供了显著的治疗益处。然而，反应率并不理想，尽管付出了相当大的努力，在给予特定患者免疫检查点抑制剂之前预测其反应仍然难以捉摸。对免疫系统和免疫检查点阻断下肿瘤的动态研究为这些治疗药物的作用机制提供了深入了解。同样相关的是通过这种方法发现的适应性抵抗免疫检查点抑制剂的机制。在这篇综述中，我们讨论了来自动物模型和人类的最近研究中免疫检查点阻断下免疫系统和肿瘤的动态。我们将重点讨论具有预测治疗反应信息的作用机制和抵抗机制。
